Comparative Pharmacology
Head-to-head clinical analysis: PYROLITE versus SELENOMETHIONINE SE 75.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PYROLITE versus SELENOMETHIONINE SE 75.
PYROLITE vs SELENOMETHIONINE SE 75
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pyrolite is not a recognized pharmaceutical drug. No mechanism of action data available.
Radiopharmaceutical agent: selenium-75 decays by electron capture to arsenic-75 with emission of gamma photons. Used as a tracer for pancreatic imaging due to incorporation into pancreatic enzymes. Localizes in pancreas via protein synthesis.
1000 mg orally every 8 hours for 7 days.
0.185-0.37 MBq (5-10 μCi) intravenously as a single dose for pancreatic imaging.
None Documented
None Documented
Terminal half-life: 4.5 hours (range 3.8–5.2). Clinical context: Eliminated rapidly; no accumulation with q6h dosing; dose adjustment needed in CrCl <30 mL/min.
Terminal half-life is approximately 50-60 days, reflecting slow turnover of selenomethionine incorporated into body proteins (e.g., skeletal muscle, erythrocytes).
Renal: 70% unchanged; Fecal: 20% as metabolites; Biliary: 10% as conjugates.
Primarily renal, with 20-30% excreted unchanged in urine; minor fecal elimination (<5%). The remainder is incorporated into endogenous proteins and long-term tissue stores.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical